Bipolar Disorder-Canada Drug Forecast and Market Analysis to 2024 – Ken Research


Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Global Data estimates the value of the Canadian bipolar disorder market to have been approximately USD 167.8m in 2014. Canada’s market size is limited by the country’s low population. Drug sales in this country are expected to stay largely constant over the forecast period, as represented by the flat CAGR. Sales are then expected to decline between 2017 and 2023 due to the generic erosion of various brands including Otsuka’s Abilify, Pfizer’s Zeldox, Allergan’s Saphris, and Janssen’s Risperdal Consta.

This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Canada from 2014-2024.

Analysis of the impact of key events as well the drivers and restraints affecting Canada Bipolar Disorder market.

Key topics covered in report

Canada Bipolar Disorder Drug Forecast

Canada Bipolar Disorder Drug Market

Canada Bipolar Disorder Drug Market Research

Canada Bipolar Disorder Drug Market Analysis

Canada Bipolar Disorder Drug Market Share

Canada Bipolar Disorder Drug Market Outlook

Canada Bipolar Disorder Drug Market Trends

Canada Bipolar Disorder Drug Market Revenue

For more coverage click on the link below:

https://www.kenresearch.com/healthcare/medical-devices/bipolar-disorder-canada-drug-forecast-market-analysis-2024/35749-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

Ankur@kenresearch.com

+91-9015378249

https://www.kenresearch.com/blog/2017/04/bipolar-disorder-canada-drug-forecast-market-analysis-2024-ken-research/

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s